Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive analysis of the immune implication of FABP4 in colon adenocarcinoma. | PLoS One | 2022 | 36264920 | PubTator, text mining | PubMed |
| Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis. | Front Genet | 2022 | 36263417 | PubTator, text mining | PubMed |
| Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. | NPJ Vaccines | 2022 | 36261460 | PubTator, text mining | PubMed |
| A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients. | Hereditas | 2022 | 36253800 | PubTator, text mining | PubMed |
| miR-aculous new avenues for cancer immunotherapy. | Front Immunol | 2022 | 36248881 | PubTator, text mining | PubMed |
| Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity. | Front Immunol | 2022 | 36248847 | PubTator, text mining | PubMed |
| Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. | Front Immunol | 2022 | 36248822 | PubTator, text mining | PubMed |
| Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction. | Front Immunol | 2022 | 36248816 | PubTator, text mining | PubMed |
| (Not) Home alone: Antigen presenting cell - T Cell communication in barrier tissues. | Front Immunol | 2022 | 36248804 | PubTator, text mining | PubMed |
| Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation. | Front Immunol | 2022 | 36248785 | PubTator, text mining | PubMed |
| Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control. | Stem Cells Int | 2022 | 36248254 | PubTator, text mining | PubMed |
| Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. | Front Genet | 2022 | 36246622 | PubTator, text mining | PubMed |
| Analysis and identification of the necroptosis landscape on therapy and prognosis in bladder cancer. | Front Genet | 2022 | 36246597 | PubTator, text mining | PubMed |
| An Integrative Multi-Omics Analysis Based on Nomogram for Predicting Prostate Cancer Bone Metastasis Incidence. | Genet Res (Camb) | 2022 | 36245556 | PubTator, text mining | PubMed |
| Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. | Cancer Biol Med | 2022 | 36245210 | PubTator, text mining | PubMed |
| ISG15 is associated with cervical cancer development. | Oncol Lett | 2022 | 36238852 | PubTator, text mining | PubMed |
| CEP192 is a novel prognostic marker and correlates with the immune microenvironment in hepatocellular carcinoma. | Front Immunol | 2022 | 36238304 | PubTator, text mining | PubMed |
| Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade. | Front Immunol | 2022 | 36238279 | PubTator, text mining | PubMed |
| Allergic Inflammation: Effect of Propolis and Its Flavonoids. | Molecules | 2022 | 36235230 | PubTator, text mining | PubMed |
| Identification of miRNAs Involved in Foetal Growth Restriction Due to Maternal Smoking during Pregnancy. | J Clin Med | 2022 | 36233676 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=46